However, as the trial did not demonstrate the benefits of durvalumab in EGFR/ALK-positive NSCLC, the use of consolidation durvalumab after curative-intent cCRT in patients with these alterations is not recommended. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.